We have read with great interest the results of the meta-analysis conducted by Li and colleagues [1], demonstrating that Janus kinase (JAK) inhibitors are a safe treatment option for patients with active ankylosing spondylitis (AS). Authors showed that JAK inhibitors might be an efficacious and safe drug class for patients with AS not responding to currently recommended biologic therapies.
